Navigation Links
BiondVax to Present Tomorrow at Joseph Gunner Pioneers 2016 Conference
Date:5/4/2016

NESS ZIONA, Israel, May 4, 2016 /PRNewswire/ --

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that BiondVax's CEO, Dr. Ron Babecoff, will be attending the Joseph Gunnar Pioneers 2016 conference in New York City.

On Thursday, May 5, Dr. Babecoff will be presenting at 10:30am at Pioneers 2016, a conference presented by Joseph Gunner & Co, taking place at the New York Palace Hotel.

The BiondVax presentation that Dr. Babecoff will be using is downloadable from BiondVax's website: http://www.biondvax.com/investor-presentation. Those wishing to meet one-on-one with Dr. Babecoff are invited to contact BiondVax.

About BiondVax Pharmaceuticals Ltd 

BiondVax is a biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. For more information, please visit http://www.biondvax.com.

Forward Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but are not limited to, the risk that drug development involves a lengthy and expensive process with uncertain outcome. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Prospectus which was declared effective on May 11, 2015. BiondVax Pharmaceuticals Ltd. undertakes no obligation to update or revise any forward-looking statements. 

For further information, please contact:  


Company Contact
Joshua Phillipson
Business Development Manager
+972-8-930-2529 x5105
j.phillipson@biondvax.com


Investor Relations Contact
GK Investor Relations
Kenny Green, Partner
+1-646-201-9246
kenny@biondvax.com


'/>"/>
SOURCE BiondVax Pharmaceuticals Ltd.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. BiondVax CEO to Present at Roth Conference on Wednesday, March 16
2. BiondVax Receives Additional Grant Approval
3. Biondvaxs Universal Flu Vaccine Receives Additional US Patent
4. BiondVax to Present on October 8 at the Aegis Growth Conference
5. BiondVax to Present on September 10 at the Rodman & Renshaw Global Investment Conference
6. Independent Results Show that BiondVaxs Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic
7. BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults
8. BiondVax Pharmaceuticals Ltd. Announces a Closing of Over-Allotment Option
9. Oramed to Present at PIONEERS 2016, Presented by Joseph Gunnar
10. TapImmune to Present at the 3rd Annual Growth Capital Expo in Las Vegas on May 4, 2016
11. Q BioMed Inc. to Present at the Global Chinese Financial Forum on April 30, 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2019)... PLAINS, N.J. (PRWEB) , ... August 14, 2019 ... ... in Lawrenceville, New Jersey has been reviewed and approved by NJ Top Docs ... care to treat his patients' urological ailments. , “Whether you require a ...
(Date:8/12/2019)... ... August 12, 2019 , ... Intalere, the healthcare industry leader in delivering ... finalist in the Innovator of The Year - Health IT category of the Pittsburgh ... by the Pittsburgh Technology Center as a healthcare IT innovator in the Pittsburgh area,” ...
(Date:8/10/2019)... ... August 10, 2019 , ... Thumb sucking is natural for infants ... 4 years of age, but past that the habit can contribute to dental problems. ... help parents know when to intervene and help their child stop the habit. , ...
Breaking Medicine Technology:
(Date:8/15/2019)... ... August 15, 2019 , ... The ASCP Foundation has ... directly affected by the closure of Hahnemann University Hospital in Philadelphia, which is ... the ASCP Foundation will be making hardship grants of up to $2,500 per ...
(Date:8/14/2019)... Colo. (PRWEB) , ... August 14, 2019 , ... Inc. ... #2008 on its annual Inc. 5000 list, the most prestigious ranking of the nation’s ... #41 among Colorado based companies and #153 in the Health sector. The list represents ...
(Date:8/14/2019)... ... August 13, 2019 , ... In a recent Trivedi Effect workshop, Master Dahryn ... belief systems. , “Doubt can obliterate your old beliefs,” said Master Dahryn. “Doubt helps ... to expand your understanding and your awareness. Trust that the Divine has put you ...
(Date:8/12/2019)... ... 2019 , ... Cryotherapy has recently been the target of negative press due ... cause of Brown’s injury was not due to cryotherapy, but due to a failure ... such as the Dallas Cowboys, the Washington Redskins, the Denver Broncos and many more, ...
(Date:8/9/2019)... LOS ANGELES (PRWEB) , ... August 09, 2019 , ... ... filed a class action complaint alleging that Mrs. Gooch's Natural Food Markets, Inc., ... California law. The Mrs. Gooch's Natural Food Markets, Inc., class action lawsuit, Case No. ...
Breaking Medicine News(10 mins):